Design, synthesis and biologival evaluation of novel isoniazid derivatives with potente antitubercular activity

Detalhes bibliográficos
Autor(a) principal: Martins, Filomena
Data de Publicação: 2014
Outros Autores: Santos, Susana, Ventura, Cristina, Elvas Leitao, Ruben, Santos, Lídia, Vitorino, Susana, Reis, Marina, Miranda, Vanessa, Correia, Henrique E., Aires-de-Sousa, João, Kovalishyn, Vasyl, Latino, Diogo A. R. S., Ramos, Jorge, Viveiros, Miguel
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.21/4932
Resumo: The disturbing emergence of multidrug-resistant strains of Mycobacterium tuberculosis (Mtb) has been driving the scientific community to urgently search for new and efficient antitubercular drugs. Despite the various drugs currently under evaluation, isoniazid is still the key and most effective component in all multi-therapeutic regimens recommended by the WHO. This paper describes the QSAR-oriented design, synthesis and in vitro antitubercular activity of several potent isoniazid derivatives (isonicotinoyl hydrazones and isonicotinoyl hydrazides) against H37Rv and two resistant Mtb strains. QSAR studies entailed RFs and ASNNs classification models, as well as MLR models. Strict validation procedures were used to guarantee the models' robustness and predictive ability. Lipophilicity was shown not to be relevant to explain the activity of these derivatives, whereas shorter N-N distances and lengthy substituents lead to more active compounds. Compounds I, 2, 4, 5 and 6, showed measured activities against H37Rv higher than INH (i.e., MIC <= 0.28 mu M), while compound 9 exhibited a six fold decrease in MIC against the katG (S315T) mutated strain, by comparison with INH (Le., 6.9 vs. 43.8 mu M). All compounds were ineffective against H37Rv(INH) (Delta katG), a strain with a full deletion of the katG gene, thus corroborating the importance of KatG in the activation of INH-based compounds. The most potent compounds were also shown not to be cytotoxic up to a concentration 500 times higher than MIC. (C) 2014 Elsevier Masson SAS. All rights reserved.
id RCAP_8ffcb1864c3787a5b95c641d642c30e1
oai_identifier_str oai:repositorio.ipl.pt:10400.21/4932
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Design, synthesis and biologival evaluation of novel isoniazid derivatives with potente antitubercular activityAntitubercular ActivityIsoniazid DerivativesMycobacterium TuberculosisResistanceQSARsSynthesisThe disturbing emergence of multidrug-resistant strains of Mycobacterium tuberculosis (Mtb) has been driving the scientific community to urgently search for new and efficient antitubercular drugs. Despite the various drugs currently under evaluation, isoniazid is still the key and most effective component in all multi-therapeutic regimens recommended by the WHO. This paper describes the QSAR-oriented design, synthesis and in vitro antitubercular activity of several potent isoniazid derivatives (isonicotinoyl hydrazones and isonicotinoyl hydrazides) against H37Rv and two resistant Mtb strains. QSAR studies entailed RFs and ASNNs classification models, as well as MLR models. Strict validation procedures were used to guarantee the models' robustness and predictive ability. Lipophilicity was shown not to be relevant to explain the activity of these derivatives, whereas shorter N-N distances and lengthy substituents lead to more active compounds. Compounds I, 2, 4, 5 and 6, showed measured activities against H37Rv higher than INH (i.e., MIC <= 0.28 mu M), while compound 9 exhibited a six fold decrease in MIC against the katG (S315T) mutated strain, by comparison with INH (Le., 6.9 vs. 43.8 mu M). All compounds were ineffective against H37Rv(INH) (Delta katG), a strain with a full deletion of the katG gene, thus corroborating the importance of KatG in the activation of INH-based compounds. The most potent compounds were also shown not to be cytotoxic up to a concentration 500 times higher than MIC. (C) 2014 Elsevier Masson SAS. All rights reserved.Elsevier France – Editions Scientifiques Medicales ElsevierRCIPLMartins, FilomenaSantos, SusanaVentura, CristinaElvas Leitao, RubenSantos, LídiaVitorino, SusanaReis, MarinaMiranda, VanessaCorreia, Henrique E.Aires-de-Sousa, JoãoKovalishyn, VasylLatino, Diogo A. R. S.Ramos, JorgeViveiros, Miguel2015-08-24T10:50:32Z2014-062014-06-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.21/4932engMARTINS, Filomena; [et al] – Design, synthesis and biologival evaluation of novel isoniazid derivaatives with potente antitubercular activity. European Journal of Medicinal Chemistry. ISSN: 0223-5234. Vol. 81 (2014), pp. 119-1380223-523410.1016/j.ejmech.2014.04.077metadata only accessinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-08-03T09:47:38Zoai:repositorio.ipl.pt:10400.21/4932Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:14:17.551830Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Design, synthesis and biologival evaluation of novel isoniazid derivatives with potente antitubercular activity
title Design, synthesis and biologival evaluation of novel isoniazid derivatives with potente antitubercular activity
spellingShingle Design, synthesis and biologival evaluation of novel isoniazid derivatives with potente antitubercular activity
Martins, Filomena
Antitubercular Activity
Isoniazid Derivatives
Mycobacterium Tuberculosis
Resistance
QSARs
Synthesis
title_short Design, synthesis and biologival evaluation of novel isoniazid derivatives with potente antitubercular activity
title_full Design, synthesis and biologival evaluation of novel isoniazid derivatives with potente antitubercular activity
title_fullStr Design, synthesis and biologival evaluation of novel isoniazid derivatives with potente antitubercular activity
title_full_unstemmed Design, synthesis and biologival evaluation of novel isoniazid derivatives with potente antitubercular activity
title_sort Design, synthesis and biologival evaluation of novel isoniazid derivatives with potente antitubercular activity
author Martins, Filomena
author_facet Martins, Filomena
Santos, Susana
Ventura, Cristina
Elvas Leitao, Ruben
Santos, Lídia
Vitorino, Susana
Reis, Marina
Miranda, Vanessa
Correia, Henrique E.
Aires-de-Sousa, João
Kovalishyn, Vasyl
Latino, Diogo A. R. S.
Ramos, Jorge
Viveiros, Miguel
author_role author
author2 Santos, Susana
Ventura, Cristina
Elvas Leitao, Ruben
Santos, Lídia
Vitorino, Susana
Reis, Marina
Miranda, Vanessa
Correia, Henrique E.
Aires-de-Sousa, João
Kovalishyn, Vasyl
Latino, Diogo A. R. S.
Ramos, Jorge
Viveiros, Miguel
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv RCIPL
dc.contributor.author.fl_str_mv Martins, Filomena
Santos, Susana
Ventura, Cristina
Elvas Leitao, Ruben
Santos, Lídia
Vitorino, Susana
Reis, Marina
Miranda, Vanessa
Correia, Henrique E.
Aires-de-Sousa, João
Kovalishyn, Vasyl
Latino, Diogo A. R. S.
Ramos, Jorge
Viveiros, Miguel
dc.subject.por.fl_str_mv Antitubercular Activity
Isoniazid Derivatives
Mycobacterium Tuberculosis
Resistance
QSARs
Synthesis
topic Antitubercular Activity
Isoniazid Derivatives
Mycobacterium Tuberculosis
Resistance
QSARs
Synthesis
description The disturbing emergence of multidrug-resistant strains of Mycobacterium tuberculosis (Mtb) has been driving the scientific community to urgently search for new and efficient antitubercular drugs. Despite the various drugs currently under evaluation, isoniazid is still the key and most effective component in all multi-therapeutic regimens recommended by the WHO. This paper describes the QSAR-oriented design, synthesis and in vitro antitubercular activity of several potent isoniazid derivatives (isonicotinoyl hydrazones and isonicotinoyl hydrazides) against H37Rv and two resistant Mtb strains. QSAR studies entailed RFs and ASNNs classification models, as well as MLR models. Strict validation procedures were used to guarantee the models' robustness and predictive ability. Lipophilicity was shown not to be relevant to explain the activity of these derivatives, whereas shorter N-N distances and lengthy substituents lead to more active compounds. Compounds I, 2, 4, 5 and 6, showed measured activities against H37Rv higher than INH (i.e., MIC <= 0.28 mu M), while compound 9 exhibited a six fold decrease in MIC against the katG (S315T) mutated strain, by comparison with INH (Le., 6.9 vs. 43.8 mu M). All compounds were ineffective against H37Rv(INH) (Delta katG), a strain with a full deletion of the katG gene, thus corroborating the importance of KatG in the activation of INH-based compounds. The most potent compounds were also shown not to be cytotoxic up to a concentration 500 times higher than MIC. (C) 2014 Elsevier Masson SAS. All rights reserved.
publishDate 2014
dc.date.none.fl_str_mv 2014-06
2014-06-01T00:00:00Z
2015-08-24T10:50:32Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.21/4932
url http://hdl.handle.net/10400.21/4932
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv MARTINS, Filomena; [et al] – Design, synthesis and biologival evaluation of novel isoniazid derivaatives with potente antitubercular activity. European Journal of Medicinal Chemistry. ISSN: 0223-5234. Vol. 81 (2014), pp. 119-138
0223-5234
10.1016/j.ejmech.2014.04.077
dc.rights.driver.fl_str_mv metadata only access
info:eu-repo/semantics/openAccess
rights_invalid_str_mv metadata only access
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier France – Editions Scientifiques Medicales Elsevier
publisher.none.fl_str_mv Elsevier France – Editions Scientifiques Medicales Elsevier
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799133400522555392